The role of medications in causing dry eye

Frederick T Fraunfelder, James J Sciubba, William D Mathers, Frederick T Fraunfelder, James J Sciubba, William D Mathers

Abstract

The purpose of this paper is to review the possible role of polypharmacy in causing dry eye disease (DED), reflecting the complex interactions and complications associated with the use of multiple systemic and topical ocular medications. The pharmacological, physiological, anatomical, and histological mechanisms causing dry mouth differ little from those causing dry eye. Oral polypharmacy is the most common cause of dry mouth, but has not been investigated as a cause of dry eye. Topical ocular polypharmacy has been shown to cause DED. Information on drugs that likely cause or aggravate DED and the controversial role of preservatives in topical ocular medications are examined. Systemic or topical ocular medications and preservatives used in topical ocular drugs may cause dry eye through the drug's therapeutic action, ocular surface effects, or preservatives, and the effects probably are additive. Long-term use of topical ocular medications, especially those containing preservatives such as BAK, may play an important role in DED and the role of polypharmacy needs further study. We review possible ways to decrease the risk of medication-related dry eye.

References

    1. Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. Investigative Ophthalmology and Visual Science. 2010;51(12):6125–6130.
    1. Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Investigative Ophthalmology and Visual Science. 2011;52(4):1922–1929.
    1. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. The Ocular Surface. 2003;1(3):107–126.
    1. Zhou S, Li Y, Lu ATH, et al. Reproducibility of tear meniscus measurement by Fourier-domain optical coherence tomography: a pilot study. Ophthalmic Surgery Lasers and Imaging. 2009;40(5):442–447.
    1. Kaufman PL, Alm A, Adler FH. Adler’s Physiology of the Eye: Clinical Application. 10th edition. St. Louis, Mo, USA: Mosby; 2003.
    1. Berkovitz BKB, Holland GR, Moxham BJ. Oral Anatomy, Histology and Embryology. 4th edition. New York, NY, USA: Mosby/Elsevier; 2009.
    1. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth—2nd edition. Gerodontology. 1997;14(1):33–47.
    1. Schein OD, Hochberg MC, Muñoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Archives of Internal Medicine. 1999;159(12):1359–1363.
    1. Guggenheimer J, Moore PA. Xerostomia: etiology, recognition and treatment. Journal of the American Dental Association. 2003;134(1):61–69.
    1. Moss SE, Klein R, Klein BEK. Long-term incidence of dry eye in an older population. Optometry and Vision Science. 2008;85(8):668–674.
    1. Moss SE, Klein R, Klein BEK. Prevalance of and risk factors for dry eye syndrome. Archives of Ophthalmology. 2000;118(9):1264–1268.
    1. Schaumberg DA, Dana R, Buring JE, Sullivan DA. Prevalence of dry eye disease among US men: estimates from the Physicians’ Health Studies. Archives of Ophthalmology. 2009;127(6):763–768.
    1. Fraunfelder FT, Fraunfelder FW, Chambers WA. Clinical Ocular Toxicology. Elsevier Saunders; 2008.
    1. PDR Staff. Physicians’Desk Reference. 64th edition. Montvale, NJ, USA: PDR Network, LLC; 2010.
    1. Foulks GN. 2007 Report of the international dry eye workshop (DEWS) The Ocular Surface. 2007;5(2):65–204.
    1. Slabaugh SL, Maio V, Templin M, Abouzaid S. Prevalence and risk of polypharmacy among the elderly in an outpatient setting: a retrospective cohort study in the Emilia-Romagna region, Italy. Drugs & Aging. 2010;27(12):1019–1028.
    1. Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: US prescription drug data for 2007–2008. NCHS Data Brief. 2010;(42):1–8.
    1. Fraunfelder FT, Gilbaugh JH. Retire Right: 8 Scientifically Proven Traits You Need for a Happy, Fulfilling Retirement. New York, NY, USA: Penguin; 2008.
    1. Osterberg T, Landahl S, Hedegard B. Salivary flow, saliva, pH and buffering capacity in 70-year-old men and women. Correlation to dental health, dryness in the mouth, disease and drug treatment. Journal of Oral Rehabilitation. 1984;11(2):157–170.
    1. Loesche WJ, Bromberg J, Terpenning MS, et al. Xerostomia, xerogenic medications and food avoidances in selected geriatric groups. Journal of the American Geriatrics Society. 1995;43(4):401–407.
    1. Persson RE, Izutsu KT, Truelove EL, Persson R. Differences in salivary flow rates in elderly subjects using xerostomatic medications. Oral Surgery, Oral Medicine, Oral Pathology. 1991;72(1):42–46.
    1. Sreebny LM, Valdini A, Yu A. Xerostomia. Part II: relationship to nonoral symptoms, drugs, and diseases. Oral Surgery, Oral Medicine, Oral Pathology. 1989;68(4 I):419–427.
    1. Rybacki JJ, Long JW. The Essential Guide To Prescription Drugs. New York, NY, USA: Harper Perennial; 1996.
    1. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Safety. 1994;10(2):93–102.
    1. Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621.
    1. Rossi GCM, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. European Journal of Ophthalmology. 2009;19(4):572–579.
    1. Pflugfelder SC. Antiinflammatory therapy for dry eye. American Journal of Ophthalmology. 2004;137(2):337–342.
    1. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994;101(3):454–460.
    1. Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115(1):109–115.
    1. Viso E, Gude F, Rodríguez-Ares MT. The association of meibomian gland dysfunction and other common ocular diseases with dry eye: a population-based study in Spain. Cornea. 2011;30(1):1–6.
    1. Hay EM, Thomas E, Pal B, Hajeer A, Chambers H, Silman AJ. Weak association between subjective symptoms of and objective testing for dry eyes and dry mouth: results from a population based study. Annals of the Rheumatic Diseases. 1998;57(1):20–24.
    1. Schein OD, Hochberg MC, Muñoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Archives of Internal Medicine. 1999;159(12):1359–1363.
    1. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. Journal of Glaucoma. 2008;17(5):350–355.
    1. Fellman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology. 2002;109(5):998–1008.
    1. Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Survey of Ophthalmology. 2004;49(2, supplement 1):S45–S52.
    1. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Survey of Ophthalmology. 1997;41(supplement 2):S105–S110.
    1. Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Progress in Retinal and Eye Research. 2010;29(4):312–334.
    1. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. European Journal of Ophthalmology. 2007;17(3):341–349.
    1. Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Archives of Ophthalmology. 1994;112(11):1446–1454.
    1. Kashkouli MB, Rezaee R, Nilforoushan N, Salimi S, Foroutan A, Naseripour M. Topical antiglaucoma medications and lacrimal drainage system obstruction. Ophthalmic Plastic and Reconstructive Surgery. 2008;24(3):172–175.
    1. Seider N, Miller B, Beiran I. Topical glaucoma therapy as a risk factor for nasolacrimal duct obstruction. American Journal of Ophthalmology. 2008;145(1):120–123.
    1. Schwab IR, Linberg JV, Gioia VM, Benson WH, Chao GM. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology. 1992;99(2):197–202.
    1. Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004;111(1):45–52.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe